Flatiron Health and Exact Sciences collaborate to use Flatiron's platform for rapid data analysis with the Oncodetect MRD test ... diverse patient groups; to do so, they will reach patients ...

Arnab Basu, MD, MPH, FACP, discusses circulating tumor DNA (ctDNA) tests with high sensitivity and specificity.

rate for its next-generation sequencing (NGS)-based clonoSEQ® test for minimal – or measurable – residual disease (MRD) assessment is now in effect as of January 1, SEATTLE, Jan. 02 ...

Unlike simultaneous, class-wide tests or exit tickets, Mastery Checks allow students to demonstrate learning at their own ...

Leveraged direct index tax loss harvesting aims to transition appreciated assets without capital gains but often results in high fees, complexity, ...

Methods The Achilles insertion of outpatients with PsA was examined by clinical assessment of tenderness and US evaluation ... and a great focus on treating to target, many patients do achieve low ...

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...

In some cases, someone may not need the money in their 401 (k) or traditional IRA and can survive in retirement on other sources, such as investments. To avoid a situation where someone skips paying ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...

In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...

In a report released on January 31, David Low from J.P. Morgan maintained a Buy rating on Resmed (RMD – Research Report), with a price target of $286.00. The company’s shares closed last ...